Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a  potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

ConclusionsThe DCAG regimen was an effective and well-tolerated therapeutic alternative for R/R AML, particularly in non-refractory patients. Patients in the poor risk category and early relapse were adverse factors for remission rate and survival.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research